The global market for AAV Gene Therapy Drugs was valued at US$ 1520 million in the year 2023 and is projected to reach a revised size of US$ 8314 million by 2030, growing at a CAGR of 26.3% during the forecast period.

AAV Gene Therapy Drugs Market

AAV gene therapy drugs are a type of biological therapeutic that utilizes adeno - associated virus (AAV) as a vector to deliver therapeutic genes into a patient's cells for the purpose of treating diseases. AAV is a small, non - enveloped, single - stranded DNA virus. It has several characteristics that make it an attractive vector for gene therapy. The virus has a relatively simple structure consisting of a protein capsid that encloses its genetic material.

North American market for AAV Gene Therapy Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for AAV Gene Therapy Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for AAV Gene Therapy Drugs in Spinal Muscular Atrophy (SMA) is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of AAV Gene Therapy Drugs include Avexis/Novartis (Zolgensma), Sarepta Therapeutics (Elevidys), Spark/Roche (Luxturna), PTC Therapeutics (Upstaza), BioMarin (Roctavian), CSL/uniQure (Hemgenix&Glybera), Pfizer, Beijing Innovikang (Pipeline), Suzhou NoJieBeig (Pipeline), Belief BioMed (Pipeline), etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for AAV Gene Therapy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding AAV Gene Therapy Drugs.

The AAV Gene Therapy Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global AAV Gene Therapy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the AAV Gene Therapy Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of AAV Gene Therapy Drugs Market Report

Report Metric	Details
Report Name	AAV Gene Therapy Drugs Market
Accounted market size in year	US$ 1520 million
Forecasted market size in 2030	US$ 8314 million
CAGR	26.3%
Base Year	year
Forecasted years	2024 - 2030
Segment by Type	scAAV9 Vector AVV2 Vector AVV5 Vector AAVrh74 Vector
Segment by Application	Spinal Muscular Atrophy (SMA) Ophthalmic Diseases Hemophilia Duchenne Muscular Dystrophy (DMD) Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Avexis/Novartis (Zolgensma), Sarepta Therapeutics (Elevidys), Spark/Roche (Luxturna), PTC Therapeutics (Upstaza), BioMarin (Roctavian), CSL/uniQure (Hemgenix&Glybera), Pfizer, Beijing Innovikang (Pipeline), Suzhou NoJieBeig (Pipeline), Belief BioMed (Pipeline)
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of AAV Gene Therapy Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is AAV Gene Therapy Drugs Market growing?

Ans: The AAV Gene Therapy Drugs Market witnessing a CAGR of 26.3% during the forecast period 2024-2030.

What is the AAV Gene Therapy Drugs Market size in 2030?

Ans: The AAV Gene Therapy Drugs Market size in 2030 will be US$ 8314 million.

Who are the main players in the AAV Gene Therapy Drugs Market report?

Ans: The main players in the AAV Gene Therapy Drugs Market are Avexis/Novartis (Zolgensma), Sarepta Therapeutics (Elevidys), Spark/Roche (Luxturna), PTC Therapeutics (Upstaza), BioMarin (Roctavian), CSL/uniQure (Hemgenix&Glybera), Pfizer, Beijing Innovikang (Pipeline), Suzhou NoJieBeig (Pipeline), Belief BioMed (Pipeline)

What are the Application segmentation covered in the AAV Gene Therapy Drugs Market report?

Ans: The Applications covered in the AAV Gene Therapy Drugs Market report are Spinal Muscular Atrophy (SMA), Ophthalmic Diseases, Hemophilia, Duchenne Muscular Dystrophy (DMD), Others

What are the Type segmentation covered in the AAV Gene Therapy Drugs Market report?

Ans: The Types covered in the AAV Gene Therapy Drugs Market report are scAAV9 Vector, AVV2 Vector, AVV5 Vector, AAVrh74 Vector

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global AAV Gene Therapy Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 scAAV9 Vector

1.2.3 AVV2 Vector

1.2.4 AVV5 Vector

1.2.5 AAVrh74 Vector

1.3 Market by Application

1.3.1 Global AAV Gene Therapy Drugs Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Spinal Muscular Atrophy (SMA)

1.3.3 Ophthalmic Diseases

1.3.4 Hemophilia

1.3.5 Duchenne Muscular Dystrophy (DMD)

1.3.6 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global AAV Gene Therapy Drugs Market Perspective (2019-2030)

2.2 Global AAV Gene Therapy Drugs Growth Trends by Region

2.2.1 Global AAV Gene Therapy Drugs Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 AAV Gene Therapy Drugs Historic Market Size by Region (2019-2024)

2.2.3 AAV Gene Therapy Drugs Forecasted Market Size by Region (2025-2030)

2.3 AAV Gene Therapy Drugs Market Dynamics

2.3.1 AAV Gene Therapy Drugs Industry Trends

2.3.2 AAV Gene Therapy Drugs Market Drivers

2.3.3 AAV Gene Therapy Drugs Market Challenges

2.3.4 AAV Gene Therapy Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top AAV Gene Therapy Drugs Players by Revenue

3.1.1 Global Top AAV Gene Therapy Drugs Players by Revenue (2019-2024)

3.1.2 Global AAV Gene Therapy Drugs Revenue Market Share by Players (2019-2024)

3.2 Global AAV Gene Therapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by AAV Gene Therapy Drugs Revenue

3.4 Global AAV Gene Therapy Drugs Market Concentration Ratio

3.4.1 Global AAV Gene Therapy Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by AAV Gene Therapy Drugs Revenue in 2023

3.5 Global Key Players of AAV Gene Therapy Drugs Head office and Area Served

3.6 Global Key Players of AAV Gene Therapy Drugs, Product and Application

3.7 Global Key Players of AAV Gene Therapy Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 AAV Gene Therapy Drugs Breakdown Data by Type

4.1 Global AAV Gene Therapy Drugs Historic Market Size by Type (2019-2024)

4.2 Global AAV Gene Therapy Drugs Forecasted Market Size by Type (2025-2030)

5 AAV Gene Therapy Drugs Breakdown Data by Application

5.1 Global AAV Gene Therapy Drugs Historic Market Size by Application (2019-2024)

5.2 Global AAV Gene Therapy Drugs Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America AAV Gene Therapy Drugs Market Size (2019-2030)

6.2 North America AAV Gene Therapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America AAV Gene Therapy Drugs Market Size by Country (2019-2024)

6.4 North America AAV Gene Therapy Drugs Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe AAV Gene Therapy Drugs Market Size (2019-2030)

7.2 Europe AAV Gene Therapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe AAV Gene Therapy Drugs Market Size by Country (2019-2024)

7.4 Europe AAV Gene Therapy Drugs Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific AAV Gene Therapy Drugs Market Size (2019-2030)

8.2 Asia-Pacific AAV Gene Therapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

8.3 Asia-Pacific AAV Gene Therapy Drugs Market Size by Region (2019-2024)

8.4 Asia-Pacific AAV Gene Therapy Drugs Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America AAV Gene Therapy Drugs Market Size (2019-2030)

9.2 Latin America AAV Gene Therapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America AAV Gene Therapy Drugs Market Size by Country (2019-2024)

9.4 Latin America AAV Gene Therapy Drugs Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa AAV Gene Therapy Drugs Market Size (2019-2030)

10.2 Middle East & Africa AAV Gene Therapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa AAV Gene Therapy Drugs Market Size by Country (2019-2024)

10.4 Middle East & Africa AAV Gene Therapy Drugs Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Avexis/Novartis (Zolgensma)

11.1.1 Avexis/Novartis (Zolgensma) Company Details

11.1.2 Avexis/Novartis (Zolgensma) Business Overview

11.1.3 Avexis/Novartis (Zolgensma) AAV Gene Therapy Drugs Introduction

11.1.4 Avexis/Novartis (Zolgensma) Revenue in AAV Gene Therapy Drugs Business (2019-2024)

11.1.5 Avexis/Novartis (Zolgensma) Recent Development

11.2 Sarepta Therapeutics (Elevidys)

11.2.1 Sarepta Therapeutics (Elevidys) Company Details

11.2.2 Sarepta Therapeutics (Elevidys) Business Overview

11.2.3 Sarepta Therapeutics (Elevidys) AAV Gene Therapy Drugs Introduction

11.2.4 Sarepta Therapeutics (Elevidys) Revenue in AAV Gene Therapy Drugs Business (2019-2024)

11.2.5 Sarepta Therapeutics (Elevidys) Recent Development

11.3 Spark/Roche (Luxturna)

11.3.1 Spark/Roche (Luxturna) Company Details

11.3.2 Spark/Roche (Luxturna) Business Overview

11.3.3 Spark/Roche (Luxturna) AAV Gene Therapy Drugs Introduction

11.3.4 Spark/Roche (Luxturna) Revenue in AAV Gene Therapy Drugs Business (2019-2024)

11.3.5 Spark/Roche (Luxturna) Recent Development

11.4 PTC Therapeutics (Upstaza)

11.4.1 PTC Therapeutics (Upstaza) Company Details

11.4.2 PTC Therapeutics (Upstaza) Business Overview

11.4.3 PTC Therapeutics (Upstaza) AAV Gene Therapy Drugs Introduction

11.4.4 PTC Therapeutics (Upstaza) Revenue in AAV Gene Therapy Drugs Business (2019-2024)

11.4.5 PTC Therapeutics (Upstaza) Recent Development

11.5 BioMarin (Roctavian)

11.5.1 BioMarin (Roctavian) Company Details

11.5.2 BioMarin (Roctavian) Business Overview

11.5.3 BioMarin (Roctavian) AAV Gene Therapy Drugs Introduction

11.5.4 BioMarin (Roctavian) Revenue in AAV Gene Therapy Drugs Business (2019-2024)

11.5.5 BioMarin (Roctavian) Recent Development

11.6 CSL/uniQure (Hemgenix&Glybera)

11.6.1 CSL/uniQure (Hemgenix&Glybera) Company Details

11.6.2 CSL/uniQure (Hemgenix&Glybera) Business Overview

11.6.3 CSL/uniQure (Hemgenix&Glybera) AAV Gene Therapy Drugs Introduction

11.6.4 CSL/uniQure (Hemgenix&Glybera) Revenue in AAV Gene Therapy Drugs Business (2019-2024)

11.6.5 CSL/uniQure (Hemgenix&Glybera) Recent Development

11.7 Pfizer

11.7.1 Pfizer Company Details

11.7.2 Pfizer Business Overview

11.7.3 Pfizer AAV Gene Therapy Drugs Introduction

11.7.4 Pfizer Revenue in AAV Gene Therapy Drugs Business (2019-2024)

11.7.5 Pfizer Recent Development

11.8 Beijing Innovikang (Pipeline)

11.8.1 Beijing Innovikang (Pipeline) Company Details

11.8.2 Beijing Innovikang (Pipeline) Business Overview

11.8.3 Beijing Innovikang (Pipeline) AAV Gene Therapy Drugs Introduction

11.8.4 Beijing Innovikang (Pipeline) Revenue in AAV Gene Therapy Drugs Business (2019-2024)

11.8.5 Beijing Innovikang (Pipeline) Recent Development

11.9 Suzhou NoJieBeig (Pipeline)

11.9.1 Suzhou NoJieBeig (Pipeline) Company Details

11.9.2 Suzhou NoJieBeig (Pipeline) Business Overview

11.9.3 Suzhou NoJieBeig (Pipeline) AAV Gene Therapy Drugs Introduction

11.9.4 Suzhou NoJieBeig (Pipeline) Revenue in AAV Gene Therapy Drugs Business (2019-2024)

11.9.5 Suzhou NoJieBeig (Pipeline) Recent Development

11.10 Belief BioMed (Pipeline)

11.10.1 Belief BioMed (Pipeline) Company Details

11.10.2 Belief BioMed (Pipeline) Business Overview

11.10.3 Belief BioMed (Pipeline) AAV Gene Therapy Drugs Introduction

11.10.4 Belief BioMed (Pipeline) Revenue in AAV Gene Therapy Drugs Business (2019-2024)

11.10.5 Belief BioMed (Pipeline) Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

AAV

Pfizer Inc

Avexis/Novartis (Zolgensma)

Sarepta Therapeutics (Elevidys)

Spark/Roche (Luxturna)

PTC Therapeutics (Upstaza)

BioMarin (Roctavian)

CSL/uniQure (Hemgenix&Glybera)

Beijing Innovikang (Pipeline)

Suzhou NoJieBeig (Pipeline)

Belief BioMed (Pipeline)

List of Tables

Table 1. Global AAV Gene Therapy Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of scAAV9 Vector

Table 3. Key Players of AVV2 Vector

Table 4. Key Players of AVV5 Vector

Table 5. Key Players of AAVrh74 Vector

Table 6. Global AAV Gene Therapy Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global AAV Gene Therapy Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global AAV Gene Therapy Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 9. Global AAV Gene Therapy Drugs Market Share by Region (2019-2024)

Table 10. Global AAV Gene Therapy Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 11. Global AAV Gene Therapy Drugs Market Share by Region (2025-2030)

Table 12. AAV Gene Therapy Drugs Market Trends

Table 13. AAV Gene Therapy Drugs Market Drivers

Table 14. AAV Gene Therapy Drugs Market Challenges

Table 15. AAV Gene Therapy Drugs Market Restraints

Table 16. Global AAV Gene Therapy Drugs Revenue by Players (2019-2024) & (US$ Million)

Table 17. Global AAV Gene Therapy Drugs Market Share by Players (2019-2024)

Table 18. Global Top AAV Gene Therapy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in AAV Gene Therapy Drugs as of 2023)

Table 19. Ranking of Global Top AAV Gene Therapy Drugs Companies by Revenue (US$ Million) in 2023

Table 20. Global 5 Largest Players Market Share by AAV Gene Therapy Drugs Revenue (CR5 and HHI) & (2019-2024)

Table 21. Global Key Players of AAV Gene Therapy Drugs, Headquarters and Area Served

Table 22. Global Key Players of AAV Gene Therapy Drugs, Product and Application

Table 23. Global Key Players of AAV Gene Therapy Drugs, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global AAV Gene Therapy Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 26. Global AAV Gene Therapy Drugs Revenue Market Share by Type (2019-2024)

Table 27. Global AAV Gene Therapy Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 28. Global AAV Gene Therapy Drugs Revenue Market Share by Type (2025-2030)

Table 29. Global AAV Gene Therapy Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 30. Global AAV Gene Therapy Drugs Revenue Market Share by Application (2019-2024)

Table 31. Global AAV Gene Therapy Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 32. Global AAV Gene Therapy Drugs Revenue Market Share by Application (2025-2030)

Table 33. North America AAV Gene Therapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 34. North America AAV Gene Therapy Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 35. North America AAV Gene Therapy Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 36. Europe AAV Gene Therapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 37. Europe AAV Gene Therapy Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 38. Europe AAV Gene Therapy Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 39. Asia-Pacific AAV Gene Therapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 40. Asia-Pacific AAV Gene Therapy Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 41. Asia-Pacific AAV Gene Therapy Drugs Market Size by Region (2025-2030) & (US$ Million)

Table 42. Latin America AAV Gene Therapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 43. Latin America AAV Gene Therapy Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 44. Latin America AAV Gene Therapy Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa AAV Gene Therapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 46. Middle East & Africa AAV Gene Therapy Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 47. Middle East & Africa AAV Gene Therapy Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 48. Avexis/Novartis (Zolgensma) Company Details

Table 49. Avexis/Novartis (Zolgensma) Business Overview

Table 50. Avexis/Novartis (Zolgensma) AAV Gene Therapy Drugs Product

Table 51. Avexis/Novartis (Zolgensma) Revenue in AAV Gene Therapy Drugs Business (2019-2024) & (US$ Million)

Table 52. Avexis/Novartis (Zolgensma) Recent Development

Table 53. Sarepta Therapeutics (Elevidys) Company Details

Table 54. Sarepta Therapeutics (Elevidys) Business Overview

Table 55. Sarepta Therapeutics (Elevidys) AAV Gene Therapy Drugs Product

Table 56. Sarepta Therapeutics (Elevidys) Revenue in AAV Gene Therapy Drugs Business (2019-2024) & (US$ Million)

Table 57. Sarepta Therapeutics (Elevidys) Recent Development

Table 58. Spark/Roche (Luxturna) Company Details

Table 59. Spark/Roche (Luxturna) Business Overview

Table 60. Spark/Roche (Luxturna) AAV Gene Therapy Drugs Product

Table 61. Spark/Roche (Luxturna) Revenue in AAV Gene Therapy Drugs Business (2019-2024) & (US$ Million)

Table 62. Spark/Roche (Luxturna) Recent Development

Table 63. PTC Therapeutics (Upstaza) Company Details

Table 64. PTC Therapeutics (Upstaza) Business Overview

Table 65. PTC Therapeutics (Upstaza) AAV Gene Therapy Drugs Product

Table 66. PTC Therapeutics (Upstaza) Revenue in AAV Gene Therapy Drugs Business (2019-2024) & (US$ Million)

Table 67. PTC Therapeutics (Upstaza) Recent Development

Table 68. BioMarin (Roctavian) Company Details

Table 69. BioMarin (Roctavian) Business Overview

Table 70. BioMarin (Roctavian) AAV Gene Therapy Drugs Product

Table 71. BioMarin (Roctavian) Revenue in AAV Gene Therapy Drugs Business (2019-2024) & (US$ Million)

Table 72. BioMarin (Roctavian) Recent Development

Table 73. CSL/uniQure (Hemgenix&Glybera) Company Details

Table 74. CSL/uniQure (Hemgenix&Glybera) Business Overview

Table 75. CSL/uniQure (Hemgenix&Glybera) AAV Gene Therapy Drugs Product

Table 76. CSL/uniQure (Hemgenix&Glybera) Revenue in AAV Gene Therapy Drugs Business (2019-2024) & (US$ Million)

Table 77. CSL/uniQure (Hemgenix&Glybera) Recent Development

Table 78. Pfizer Company Details

Table 79. Pfizer Business Overview

Table 80. Pfizer AAV Gene Therapy Drugs Product

Table 81. Pfizer Revenue in AAV Gene Therapy Drugs Business (2019-2024) & (US$ Million)

Table 82. Pfizer Recent Development

Table 83. Beijing Innovikang (Pipeline) Company Details

Table 84. Beijing Innovikang (Pipeline) Business Overview

Table 85. Beijing Innovikang (Pipeline) AAV Gene Therapy Drugs Product

Table 86. Beijing Innovikang (Pipeline) Revenue in AAV Gene Therapy Drugs Business (2019-2024) & (US$ Million)

Table 87. Beijing Innovikang (Pipeline) Recent Development

Table 88. Suzhou NoJieBeig (Pipeline) Company Details

Table 89. Suzhou NoJieBeig (Pipeline) Business Overview

Table 90. Suzhou NoJieBeig (Pipeline) AAV Gene Therapy Drugs Product

Table 91. Suzhou NoJieBeig (Pipeline) Revenue in AAV Gene Therapy Drugs Business (2019-2024) & (US$ Million)

Table 92. Suzhou NoJieBeig (Pipeline) Recent Development

Table 93. Belief BioMed (Pipeline) Company Details

Table 94. Belief BioMed (Pipeline) Business Overview

Table 95. Belief BioMed (Pipeline) AAV Gene Therapy Drugs Product

Table 96. Belief BioMed (Pipeline) Revenue in AAV Gene Therapy Drugs Business (2019-2024) & (US$ Million)

Table 97. Belief BioMed (Pipeline) Recent Development

Table 98. Research Programs/Design for This Report

Table 99. Key Data Information from Secondary Sources

Table 100. Key Data Information from Primary Sources

Table 101. Authors List of This Report

List of Figures

Figure 1. AAV Gene Therapy Drugs Picture

Figure 2. Global AAV Gene Therapy Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global AAV Gene Therapy Drugs Market Share by Type: 2023 VS 2030

Figure 4. scAAV9 Vector Features

Figure 5. AVV2 Vector Features

Figure 6. AVV5 Vector Features

Figure 7. AAVrh74 Vector Features

Figure 8. Global AAV Gene Therapy Drugs Market Size by Application (2024-2030) & (US$ Million)

Figure 9. Global AAV Gene Therapy Drugs Market Share by Application: 2023 VS 2030

Figure 10. Spinal Muscular Atrophy (SMA) Case Studies

Figure 11. Ophthalmic Diseases Case Studies

Figure 12. Hemophilia Case Studies

Figure 13. Duchenne Muscular Dystrophy (DMD) Case Studies

Figure 14. Others Case Studies

Figure 15. AAV Gene Therapy Drugs Report Years Considered

Figure 16. Global AAV Gene Therapy Drugs Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 17. Global AAV Gene Therapy Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 18. Global AAV Gene Therapy Drugs Market Share by Region: 2023 VS 2030

Figure 19. Global AAV Gene Therapy Drugs Market Share by Players in 2023

Figure 20. Global Top AAV Gene Therapy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in AAV Gene Therapy Drugs as of 2023)

Figure 21. The Top 10 and 5 Players Market Share by AAV Gene Therapy Drugs Revenue in 2023

Figure 22. North America AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. North America AAV Gene Therapy Drugs Market Share by Country (2019-2030)

Figure 24. United States AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Canada AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Europe AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Europe AAV Gene Therapy Drugs Market Share by Country (2019-2030)

Figure 28. Germany AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. France AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. U.K. AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Italy AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Russia AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Nordic Countries AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Asia-Pacific AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Asia-Pacific AAV Gene Therapy Drugs Market Share by Region (2019-2030)

Figure 36. China AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Japan AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. South Korea AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Southeast Asia AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. India AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Australia AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Latin America AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Latin America AAV Gene Therapy Drugs Market Share by Country (2019-2030)

Figure 44. Mexico AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Brazil AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Middle East & Africa AAV Gene Therapy Drugs Market Share by Country (2019-2030)

Figure 48. Turkey AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Saudi Arabia AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 50. UAE AAV Gene Therapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 51. Avexis/Novartis (Zolgensma) Revenue Growth Rate in AAV Gene Therapy Drugs Business (2019-2024)

Figure 52. Sarepta Therapeutics (Elevidys) Revenue Growth Rate in AAV Gene Therapy Drugs Business (2019-2024)

Figure 53. Spark/Roche (Luxturna) Revenue Growth Rate in AAV Gene Therapy Drugs Business (2019-2024)

Figure 54. PTC Therapeutics (Upstaza) Revenue Growth Rate in AAV Gene Therapy Drugs Business (2019-2024)

Figure 55. BioMarin (Roctavian) Revenue Growth Rate in AAV Gene Therapy Drugs Business (2019-2024)

Figure 56. CSL/uniQure (Hemgenix&Glybera) Revenue Growth Rate in AAV Gene Therapy Drugs Business (2019-2024)

Figure 57. Pfizer Revenue Growth Rate in AAV Gene Therapy Drugs Business (2019-2024)

Figure 58. Beijing Innovikang (Pipeline) Revenue Growth Rate in AAV Gene Therapy Drugs Business (2019-2024)

Figure 59. Suzhou NoJieBeig (Pipeline) Revenue Growth Rate in AAV Gene Therapy Drugs Business (2019-2024)

Figure 60. Belief BioMed (Pipeline) Revenue Growth Rate in AAV Gene Therapy Drugs Business (2019-2024)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions